ID 641 - Kwas dokozaheksaenowy, Kwas eikozapentaenowy, Kwas gamma-linolenowy

PL: Kwas dokozaheksaenowy, Kwas eikozapentaenowy, Kwas gamma-linolenowy
EN: Omega-3 (DHA, EPA) and Omega-6 fatty acids (GLA)
Pdf: DHA, EPA and GLA

Oświadczenie (2)

1.4. Ograniczenie zapalenia (ID 546, 547, 641, 2505, 2862)

The claimed effects are "regulation of metabolic function", "molecule precursors regulating cell functions (prostaglandins, leucotrienes)", "supportive measure for healthy inflammatory responses", "kidneys health" and "regulation of inflammatory responses in the body". The Panel assumes that the target population is the general population.
In the context of the proposed wordings and the clarifications provided by Member States, the Panel assumes that the claimed effects refer to the reduction of inflammation.
Inflammation is a non-specific physiological response to tissue damage which is mediated by the immune system. Adequate inflammatory responses are of primary importance for the defence against injury of any origin. Changes in markers of inflammation such as various interleukins do not indicate a beneficial physiological effect per se but should be linked to a beneficial physiological or clinical outcome. The Panel considers that no evidence has been provided to indicate the context in which the claimed effect could be considered to be a beneficial physiological effect.
For ID 2862 the suppression of pro-inflammatory cytokine production (e.g. TNF-α) was mentioned in the clarifications provided, and additional inflammatory markers (e.g. prostaglandin E2,
inhibitor-kappa-B-kinase, IL-8, NFkappaB) were addressed in the in vitro studies provided for the scientific substantiation of the claim. The Panel considers that no evidence has been provided to indicate the context in which the changes in these markers could indicate a beneficial physiological effect in humans.
The Panel concludes that a cause and effect relationship has not been established between the consumption of the food(s)/food constituent(s), which are the subject of the health claims, and a beneficial physiological effect related to the reduction of inflammation.

Warunki i możliwe ograniczenia stosowania oświadczenia

360-540 mg GLA/day (current knowledge: GLA/EPA ratio lower or equal to 6/1)